相关临床试验
4
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2007
进行中（未招募）
1
25.0%
已完成
1
25.0%
招募中
1
25.0%
撤回
1
25.0%
暂无批准数据
- Over 25 pharmaceutical companies are actively developing 30+ TGF-β inhibitors to address significant unmet needs in oncology and fibrosis where existing therapies show limited effectiveness. - Key pipeline advances include Keros Therapeutics initiating Phase III trials for elritercept in myelodysplastic syndromes and EpicentRx receiving FDA Fast Track designation for AdAPT-001 in soft tissue sarcoma. - Recent clinical milestones demonstrate promising efficacy across multiple indications, with companies like Isarna Therapeutics reporting positive Phase II results for retinal fibrosis treatment ISTH0036.
- Bloomage Biotech invested HKD 138 million in Sirnaomics at HKD 12 per share, acquiring a 9.44% stake to accelerate development of RNAi therapeutics in aesthetics, longevity, and regenerative medicine. - The strategic partnership combines Sirnaomics' proprietary PNP and GalAhead™ delivery platforms with Bloomage's hyaluronic acid expertise and commercial capabilities in Greater China. - The collaboration will focus on advancing Sirnaomics' STP705 targeted fat reduction program and developing next-generation precision-delivery solutions for aesthetic applications. - This investment allows Sirnaomics to allocate internal resources toward oncology and autoimmune disease programs while leveraging Bloomage's strengths in the aesthetics portfolio.
- More than 12 MCL-1 inhibitor drugs are currently progressing through clinical trials, representing a significant therapeutic opportunity for cancer treatment. - Next-generation approaches including PROTACs for selective MCL-1 degradation and precision medicine tools like BH3 profiling are advancing the field beyond traditional inhibition strategies. - The MCL-1 inhibitor market faces a critical paradox between clear therapeutic need and major safety barriers, with combination therapies emerging as a promising commercialization strategy. - Global expansion into developing markets including China, Japan, and South Korea is creating new opportunities for clinical testing and commercialization of MCL-1 targeting therapies.
- DelveInsight's latest report reveals a robust pipeline with over 20 companies developing 25+ therapies for metastatic liver cancer, offering new hope for patients with limited treatment options. - Several promising clinical trials are underway in 2025, including studies evaluating novel combinations such as AK104 plus lenvatinib, tislelizumab with lenvatinib, and triplet therapy of nivolumab, relatlimab and bevacizumab. - Key emerging therapies include exoASO-STAT6 targeting tumor-associated macrophages, STP705 dual TGF-ß1/COX-2 inhibitor, and ONCR-177, an oncolytic viral immunotherapy expressing five transgenes to fight tumors through multiple mechanisms.
